… Based on the rationales, we hypothesized that low-dose erlotinib would be safe and …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …

… sorafenib and erlotinib in previously treated patients with advanced NSCLC. … , phase II study
to evaluate efficacy and safety of combination of sorafenib with erlotinib in previously treated…

… treated with bevacizumab plus erlotinib also showed improved PFS (HR = 0.48; 95% CI,
0.27–0.84; p = 0.008). Grade ≥3 treatment-… Bevacizumab plus erlotinib significantly improved …

… in Caucasian patients treated in routine clinical setting is limited we conducted a multicenter,
phase IV clinical trial to determine the efficacy and safety of erlotinib and to demonstrate the …

… Adding bevacizumab to erlotinib prolonged PFS in NEJ026 and CTONG 1509 trials, …
multicenter phase III trial of bevacizumab (BEV) plus erlotinib (E) vs E alone as first-line treatment …

… Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) … multicenter,
randomized, phase 3 investigating the addition of bevacizumab to erlotinib as first-line treatment …

… Our study showed that, compared with patients with EGFR exon 19 deletion, patients with
exon 21 mutation had prolonged PFS after erlotinib treatment, suggesting erlotinib combined …

… full-dose erlotinib for … erlotinib seems too toxic as maintenance therapy. This study aimed
to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment …

… We report on the long-term results of first-line treatment with erlotinib in Caucasian patients
with advanced adenocarcinoma of the lung that have a somatic EGFR mutation in their tumor…

… E arm was treated with oral erlotinib (150mg/day for 2 years or till either disease … days/week
for 6 weeks from first day erlotinib). EP arm was treated with sequential etoposide (50 mg/m …